Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Description Statussort icon Initial Date
<a href="/venture-capital/all-companies/pronutria">Pronutria</a> Transforming medicine with ProNutrein™ products, protein nutrients identified in the human diet, for the dietary management of disease. Private 2010 View Profile
<a href="/venture-capital/all-companies/seres-health">Seres Health</a> Discovering and developing Ecobiotic® therapeutic products to treat important diseases by targeting the underlying biology of the human microbiome. Private 2012 View Profile
<a href="/venture-capital/all-companies/midori-renewables-inc">Midori Renewables Inc.</a> Deploying Breaking the Biomass Barrier™ technology that melts and digests biomass into sugars. Private 2009 View Profile
<a href="/venture-capital/all-companies/blend-therapeutics-inc">Blend Therapeutics Inc.</a> Discovering new classes of medicines that have unique modes of action to result in drugs with differentiated therapeutic properties. Private 2012 View Profile
<a href="/venture-capital/all-companies/tangent-medical-technologies-inc">Tangent Medical Technologies Inc.</a> Developing and commercializing IV therapy products. Private 2011 View Profile
<a href="/venture-capital/all-companies/syros-pharmaceuticals-0">Syros Pharmaceuticals</a> Harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Private 2012 View Profile
<a href="/venture-capital/all-companies/ecosense-lighting%C2%AE">EcoSense Lighting®</a> Providing best-in-class LED lighting solutions for use in architectural applications. Private 2013 View Profile
<a href="/venture-capital/all-companies/editas-medicine">Editas Medicine</a> Unlocking the promise of genome editing to deliver life-changing medicines. Private 2013 View Profile
<a href="/venture-capital/all-companies/bg-medicine-inc">BG Medicine, Inc.</a> Developing and delivering diagnostic solutions to aid in the clinical management of heart failure and related disorders. Public 2000 View Profile
<a href="/venture-capital/all-companies/agios-pharmaceuticals-inc">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs to treat cancer and inborn errors of metabolism. Public 2007 View Profile
<a href="/venture-capital/all-companies/concert-pharmaceuticals-inc">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Public 2006 View Profile
<a href="/venture-capital/all-companies/t2-biosystems-inc">T2 Biosystems, Inc.</a> Using T2MR to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare. Public 2006 View Profile
<a href="/venture-capital/all-companies/acceleron-pharma-inc">Acceleron Pharma, Inc.</a> Discovering, developing and commercializing novel protein therapeutics for cancer and rare diseases. Public 2004 View Profile
<a href="/venture-capital/all-companies/bind-therapeutics-inc">BIND Therapeutics, Inc.</a> Developing Accurins, its novel targeted therapeutics. Public 2007 View Profile
<a href="/venture-capital/all-companies/eleven-biotherapeutics-inc">Eleven Biotherapeutics, Inc.</a> Discovering and developing protein therapeutics to treat diseases of the eye. Public 2008 View Profile